Gallant is a new breed of biotechnology company, advancing the field of regenerative medicine and bringing life-changing therapies to pets everywhere. Gallant was formed in 2018 by Aaron Hirschhorn (founder DogVacay/Rover) and top scientists in the field (Dr. Linda Black, Dr. Ted Sand) with over 100 years of combined stem cell research experience.
Gallant has raised $20m from top VCs (Maveron, Bold, Slow) and their advisors include industry heavyweights like Darryl Rawlings (Trupanion), Richard Jennings (Cryobank), Anne Wojcicki (23&Me), Art Antin (VCA), and more. In addition to national press coverage (USA Today, Forbes), Gallant was featured on ABC’s Shark Tank in November 2019.
Gallant’s work has led to the development of a cell therapy platform with four allogeneic (off-the-shelf) therapeutic assets in the current development pipeline. One of these assets has garnered a top-3 animal health company development partnership, with others in the making.
As part of the FDA Center for Veterinary Medicine Veterinary Innovation Program (VIP) that helps innovative products fast-track to market, Gallant is positioned for rapid product approvals. The core team is composed of industry pioneers with deep experience and expertise in translating cell therapies from the bench to the clinic, along with strengths in clinical development, regulatory, and cGMP manufacturing. Gallant has robust IP protection with 5 patents issued and 13 pending applications.
Located in the La Jolla area, Gallant’s new 7000 SF headquarters support a large R&D laboratory, a cGMP and ISO7 compliant manufacturing laboratory and office space, with room to grow. Gallant has a diverse team of 20 dog-loving employees and fosters an inclusive, positive, high energy and connected culture.